extensively in a large range of indications, particularly central nervous system examinations, as well as neurodegenerative diseases and tumoural disease processes, among others.
Contrast enhancement has enabled improved tissue contrast and lesion characterisation and more sensitive detection of even very small lesions. The differences between the molecular structures of the gadolinium chelates affect their physicochemical characteristics.
Greater importance has recently been placed on GBCAs and chelate stability, particularly with the possible association between the development of nephrogenic systemic fibrosis (NSF) in patients with kidney failure. [1] [2] [3] In response to the growing interest in this topic, this article will address the differences between gadolinium-based MRI contrast agents with regard to their molecular structure and physicochemical properties, providing evidence of the advantages of some compounds in terms of stability, relaxivity and concentration.
Molecular Structure and Physicochemical Characteristics
GBCAs consist of the active substance gadolinium and a chelating agent. They can be categorised by their chemical structures into linear and macrocyclic agents and further subdivided by their charge (ionic or non-ionic). While differences do exist among the gadolinium compounds in terms of various physicochemical characteristics, stability, concentration and relaxivity appear to have a major clinical impact.
Stability
The chelation of gadolinium to organic ligands promotes biodistribution within the extracellular interstitial space while enhancing renal filtration. 2 After intravenous administration, GBCAs distribute into accessible extracellular spaces, with a distribution half-life of approximately 10 minutes. 4 GBCAs are typically excreted by the kidneys, with an elimination half-life of approximately 90 minutes in patients with normal renal function. Over 90% of the injected dose is eliminated renally within the first 24 hours. 2, 5 By comparison, patients with reduced kidney function encounter a prolonged elimination halflife of several hours, depending on the degree of renal impairment, with >80% of the administered dose excreted over the subsequent week. 6 Notably, renal impairment does not affect the extracellular distribution half-life. 7 The greatest concern regarding the stability of gadolinium chelates relates to the risk of transmetallation, where gadolinium has the potential to be exchanged between ligands or even be released as a free Gd 3+ ion and retained within the body. Great emphasis has been placed on gadolinium chelate stability in vivo and patient safety in recent years, particularly given the possible association with the occurence of NSF. [1] [2] [3] gadolinium chelates are generally more stable than their linear counterparts. 8, 9 In a recent investigation into the stability of GBCAs, the rates of dissociation of Gd 3+ ions were determined by incubating the gadolinium compounds in human serum over 15 days at 1mmol/l under physiological conditions (pH 7.4, 37°C). 9 The non-ionic linear gadolinium chelates were found to be the least stable, with the greatest propensity to release Gd 3+ ions into native human serum.
Non-ionic chelates were followed by ionic linear compounds and finally macrocyclic compounds (see Figure 2A and increased by approximately 100-fold. These two contrast agents are similar in that both are linear, non-ionic agents and have the lowest thermodynamic stability constant among the GBCAs. After 15 days, gadodiamide and gadoversetamide had released about 37% of the total amount of Gd 3+ , which is roughly 1.8-fold compared with native serum (see Figure 2B ). While the ionic linear compounds also exhibited a 12-30-fold accelerated rate of Gd 3+ release in the presence of elevated phosphate levels, the total amount of Gd 3+ released after 15 days was comparable to that of native serum.
Notably, the elevated phosphate levels had no discernable effect on the release of Gd 3+ ions from the macrocyclic contrast agents. The
GBCAs can therefore be divided into three distinct stability classes:
non-ionic linear agents, ionic linear agents and macrocyclic agents.
Relaxivity and Concentration
The relaxivity and concentration of any given contrast medium are properties that contribute to an agent's efficacy via the shortening of relaxation times and the resulting enhancement. By definition, relaxivity values are concentration-normalised data. Being independent of gadolinium concentration, the effects of local concentrations of contrast are not accounted for. The relaxivity of different gadolinium chelates had previously been shown to decrease at increasing magnetic field strengths (see Figure 3) . 10 Significantly different dependencies of relaxivities on field strength exist between GBCAs.
Gadobutrol (Gadovist), gadobenate dimeglumine (MultiHance) and the liver-specific gadoxetic acid (Primovist) consistently exhibited higher relaxivity relative to the other compounds across the different magnetic fields that are commonly used in clinical practice.
T1 shortening -the parameter that directly influences the available signal intensity in T1-weighted, contrast-enhanced MRI -is also affected by the concentration of the contrast medium. The local contrast medium concentration in turn depends on a number of intrinsic, physical and technical factors, including:
• the cardiovascular physiology of a particular individual;
• the region of interest;
• the injection rate (ml/s);
• the injected dose (mmol); and
• the concentration of the injected contrast agent.
In one study using an animal model, identical bolus injections of gadobutrol at two different concentrations resulted in a higher concentration in the common carotid artery by approximately 30%
with the 1.0M solution compared with the 0.5M solution. 11 Many other studies have since demonstrated a concentration-dependent effect on T1 shortening and imaging enhancement.
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Greater Enhancement and Improved Detection 17 It is also possible that a better-defined bolus stemming from this improved bolus effect may also enhance the contrast-to-noise ratio (CNR) and therefore the imaging characteristics of first-pass MRI techniques. 18 Tombach et al. had previously compared gadobutrol at concentrations of 0.5 and 1.0M in an intra-individually controlled study with magnetic resonance brain perfusion imaging. 19 With the higher-concentration formulation of 1.0M, a significantly smaller bolus width was achieved at the half maximum signal intensity decrease. Moreover, the smaller mean peak time observed, higher contrast and higher signal-to-noise ratio (SNR) ultimately led to better brain perfusion images than those obtained with the 0.5M formulation.
In another study where 0.5M gadopentetate (Magnevist), 0.5 M gadobenate and 1.0M gadobutrol were compared in a pelvic 3D
MRA setting, the quality of images obtained with either gadobutrol or gadobenate were similar in their superiority over those obtained by gadopentetate when administered at an equal dose and injection rate. 20 Undiluted gadobutrol performed better than its highly concentrated and compact bolus of gadobutrol can confer substantial improvements in image quality, quantifiable through significantly higher SNRs and CNRs.
Several studies have evaluated the effects of gadolinium chelates on the shortening of relaxation times and contrast enhancement, knowing that there is an influence on these outcomes by both relaxivity and concentration. Data originating from a rat brain tumour model show that the application of gadobutrol at the same gadolinium dose per weight results in markedly higher SNR and CNR values than gadopentetate and gadoterate at three Tesla (3T).
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Superior enhancement was observed with the double-concentrated gadobutrol at each post-contrast time-point assessed.
More recent studies have compared the use of 0.5 and 1.0M
contrast agents in the imaging of brain tumours. One study used exogenous contrast-based, T 2 *-weighted, gradient-recalled echoplanar imaging to determine intracranial perfusion characteristics in 11 patients (six with intra-axial and five with extra-axial tumours).
Patients received either 5ml of 1.0M gadobutrol or 10ml of 0.5M
gadopentetate. 22 The investigators assessed the maximal signal change in the region of interest as the primary outcome measure for perfusion-weighted imaging. They found that at 3T, the higher concentration of 1.0M gadobutrol provided significantly better delineation between grey and white matter. It also better defined the presence of highly vascularised brain tumour tissue than the standard 0.5M strength gadopentetate.
Visualisation of brain metastases has also been reported to be significantly improved with gadobutrol over gadopentetate and the detected lesions were more conspicuous. 16 In this study, equal gadolinium dosages of each contrast agent were injected in a fully randomised sequence into 27 patients with at least one cerebral metastasis, with 18 hours between examinations with contrastenhanced MRI. A total of 67 metastatic lesions were detected using gadobutrol enhancement compared with 65 lesions detected with gadopentetate; in two cases lesions were observed only with gadobutrol (see Figure 4) . A comparison of images on a qualitative level by two fully blinded and experienced neuroradiologists revealed improved lesion conspicuity with gadobutrol in 10/27 of cases (p=0.002; see Figure 5 ). The comparison also revealed equivalent conspicuity in 17/27 cases, with no reported improvements in conspicuity for gadopentetate over gadobutrol.
The results from these small studies suggest that highly concentrated GBCAs confer significant advantages in imaging enhancement.
Summary and Conclusions
The differences between the physicochemical properties of GBCAs have an impact on the stability of the chelate. 16 Reprinted with permission.
